That changed on July 24, when the Food and Drug Administration approved Lytenava, an ophthalmic version of bevacizumab, for neovascular age-related macular degeneration. For the roughly one million Americans living with the wet form of macular degeneration, the practical question is whether an approved product changes what they receive at their next appointment. The confirmed fact is that an ophthalmic formulation of bevacizumab now has FDA approval for wet AMD after two decades of off-label use. It is the first bevacizumab product approved in the United States specifically for injection into the eye. Retina specialists have used it off-label for wet AMD because it is far cheaper than approved alternatives, with compounding pharmacies repackaging vials into injection-sized doses.